Joseph Stringer
Stock Analyst at Needham
(2.95)
# 1,433
Out of 4,748 analysts
284
Total ratings
36.96%
Success rate
1.37%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Stringer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LXRX Lexicon Pharmaceuticals | Reiterates: Hold | n/a | $0.83 | - | 11 | Jan 29, 2025 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Buy | $320 | $273.99 | +16.79% | 17 | Jan 13, 2025 | |
| PHAT Phathom Pharmaceuticals | Reiterates: Buy | $28 | $6.55 | +327.48% | 47 | Jan 10, 2025 | |
| STOK Stoke Therapeutics | Maintains: Buy | $22 | $10.51 | +109.32% | 19 | Jan 8, 2025 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Hold | n/a | $441.52 | - | 3 | Dec 20, 2024 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $60 | $32.88 | +82.48% | 17 | Dec 20, 2024 | |
| VIR Vir Biotechnology | Reiterates: Buy | $19 | $10.90 | +74.31% | 15 | Nov 20, 2024 | |
| ANNX Annexon | Reiterates: Buy | $16 | $4.12 | +288.35% | 17 | Nov 15, 2024 | |
| RNA Avidity Biosciences | Reiterates: Buy | $60 | $31.92 | +87.97% | 15 | Nov 13, 2024 | |
| MRNA Moderna | Reiterates: Hold | n/a | $40.72 | - | 8 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $95.59 | - | 3 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $55 → $64 | $57.19 | +11.91% | 18 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $140 | $88.67 | +57.89% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $60 | $29.47 | +103.60% | 19 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $1.42 | +1,519.72% | 16 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $17.85 | +40.06% | 8 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $10.74 | +253.82% | 14 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $4.99 | - | 16 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $37 | $18.37 | +101.42% | 6 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $18 | $9.63 | +86.92% | 2 | Aug 24, 2021 |
Lexicon Pharmaceuticals
Jan 29, 2025
Reiterates: Hold
Price Target: n/a
Current: $0.83
Upside: -
Alnylam Pharmaceuticals
Jan 13, 2025
Reiterates: Buy
Price Target: $320
Current: $273.99
Upside: +16.79%
Phathom Pharmaceuticals
Jan 10, 2025
Reiterates: Buy
Price Target: $28
Current: $6.55
Upside: +327.48%
Stoke Therapeutics
Jan 8, 2025
Maintains: Buy
Price Target: $22
Current: $10.51
Upside: +109.32%
Vertex Pharmaceuticals
Dec 20, 2024
Reiterates: Hold
Price Target: n/a
Current: $441.52
Upside: -
Ionis Pharmaceuticals
Dec 20, 2024
Maintains: Buy
Price Target: $60
Current: $32.88
Upside: +82.48%
Vir Biotechnology
Nov 20, 2024
Reiterates: Buy
Price Target: $19
Current: $10.90
Upside: +74.31%
Annexon
Nov 15, 2024
Reiterates: Buy
Price Target: $16
Current: $4.12
Upside: +288.35%
Avidity Biosciences
Nov 13, 2024
Reiterates: Buy
Price Target: $60
Current: $31.92
Upside: +87.97%
Moderna
Nov 8, 2024
Reiterates: Hold
Price Target: n/a
Current: $40.72
Upside: -
Nov 7, 2024
Reiterates: Hold
Price Target: n/a
Current: $95.59
Upside: -
Nov 6, 2024
Maintains: Buy
Price Target: $55 → $64
Current: $57.19
Upside: +11.91%
Nov 6, 2024
Reiterates: Buy
Price Target: $140
Current: $88.67
Upside: +57.89%
Nov 6, 2024
Maintains: Buy
Price Target: $85 → $60
Current: $29.47
Upside: +103.60%
Nov 6, 2024
Reiterates: Buy
Price Target: $23
Current: $1.42
Upside: +1,519.72%
Aug 14, 2024
Reiterates: Buy
Price Target: $25
Current: $17.85
Upside: +40.06%
Aug 8, 2024
Reiterates: Buy
Price Target: $38
Current: $10.74
Upside: +253.82%
Jun 13, 2024
Downgrades: Hold
Price Target: n/a
Current: $4.99
Upside: -
Jan 24, 2024
Upgrades: Buy
Price Target: $37
Current: $18.37
Upside: +101.42%
Aug 24, 2021
Maintains: Buy
Price Target: $32 → $18
Current: $9.63
Upside: +86.92%